Status:
COMPLETED
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
Lead Sponsor:
AstraZeneca
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of ...
Eligibility Criteria
Inclusion
- Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
- Percutaneous coronary intervention (PCI) planned,
- Evidence of coronary artery disease
Exclusion
- Hypersensitivity to statins
- Any cholesterol lowering medication taken within 1 month prior V1
- Sustained ST-segment elevation on ECG
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
1160 Patients enrolled
Trial Details
Trial ID
NCT00296387
Start Date
January 1 2006
End Date
October 1 2007
Last Update
December 17 2007
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalst, Belgium
2
Research Site
Bonheiden, Belgium
3
Research Site
Bouge, Belgium
4
Research Site
Brussels, Belgium